John W. Huemoeller II | Source | Chief Executive Officer at AXIM Biotechnologies

We are extremely excited with the results of the in vitro testing. This potential therapeutic treatment could someday help control melanoma growth and metastasis with our compound SPX-1009 in a topical treatment.

With this amended EUA, we are one step closer to our goal of providing an ‘Immunity Passport’ through our accurate, fast and relatively inexpensive COVID-19 neutralizing antibody test. Our assay is the only functional test that measures levels of neutralizing antibodies in serum, plasma or whole blood.